Drug Immunology

Tremfya

Payments companies reported to CMS as associated with Tremfya. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$65Massociated payments (2023-2025)

49,557clinicians with associated payments

7companies reporting

By year

2023 $11M

2024 $23M

2025 $30M

Payments reported as associated with Tremfya, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Dermatology $18M

Gastroenterology (Internal Medicine) $15M

Rheumatology $8.9M

Physician Assistant $7.7M

Family $3.2M

Medical $2.2M

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tremfya

These are the largest totals companies reported as associated with Tremfya. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Lori Cox	New Brunswick, NJ	Rheumatology	$441,467.50
Steven Feldman	Winston Salem, NC	Dermatology	$365,247.43
Nicole Seminara	Huntersville, NC	Dermatology	$343,950.51
Reeli Reinu	Maitland, FL	Physician Assistant	$336,749.50
Aaron Sookhoo	Brandon, FL	Surgical	$328,979.44
George Lewitt	Northbrook, IL	Dermatology	$326,863.14
Scott Gottlieb	Exton, PA	Dermatology	$317,055.84
Saakshi Khattri	New York, NY	Dermatology	$288,879.98
Scott Guenthner	Plainfield, IN	Dermatology	$277,848.41
Jana Johnson	Sioux Falls, SD	Dermatology	$276,342.78

Prescribed Tremfya?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.